WorldCat Identities

Fox Chase Cancer Center

Overview
Works: 112 works in 245 publications in 1 language and 457 library holdings
Genres: Periodicals  Conference proceedings 
Classifications: RC267, 616
Publication Timeline
.
Most widely held works by Fox Chase Cancer Center
Scientific report ( )
in English and held by 187 WorldCat member libraries worldwide
Institute for cancer research : twenty-ninth scientific report ; and, American Oncologic Hospital : first scientific report ( Book )
1 edition published in 1984 in English and held by 8 WorldCat member libraries worldwide
Fox Chase Cancer Center : Scientific Report, 1996 by Fox Chase Cancer Center( Book )
2 editions published between 1996 and 1997 in English and held by 7 WorldCat member libraries worldwide
Scientific report by Fox Chase Cancer Center( Book )
2 editions published in 1986 in English and held by 7 WorldCat member libraries worldwide
Tailored Communication to Enhance Adaption Across the Breast Cancer Spectrum ( )
6 editions published between 2002 and 2007 in English and held by 6 WorldCat member libraries worldwide
The Behavioral Center of Excellence (BCE) in Breast Cancer was established to provide a comprehensive, multi disciplinary approach for studying the process of, and methods for facilitating, successful adaptation in the context of breast cancer risk, treatment, and recovery. The four ongoing studies are derived from and integrated by a unifying theoretical framework, and are supported by four core facilities (i.e., Administrative, Communication, Genetic Testing and Bioinformatics Core). The four projects are: I) development of an intervention to promote utilization of breast cancer risk assessment programs and adherence to screening recommendations among underserved African-American women; 2) use of a "teachable moment" and tailored communication materials to promote utilization of risk assessment and adherence to screening among daughters of diagnosed breast cancer patients; 3) the promotion of psychological and physical adaptation among breast cancer patients at the completion of active treatment(i.e., during the re-entry phase); 4) promotion of psychological adaptation among metastatic breast cancer patients. The overarching goal is to develop theoretically guided, tailored, and transportable breast cancer communications to enhance screening adherence, decision-making, and quality of life across the spectrum of disease (i.e., from risk through treatment to survivorship)
Establishment of the Fox Chase Network Breast Cancer Risk Registry ( )
6 editions published between 1995 and 1998 in English and held by 6 WorldCat member libraries worldwide
The wealth of research regarding the complex interaction of the genetic, biologic and environmental factors associated with breast carcinogenesis offers promise towards better understanding of breast cancer. The progress in molecular genetics provides us with opportunities to expand our knowledge about modifiable causes of breast cancer. The development of the Fox Chase Cancer Center Breast Cancer Risk Registry was proposed to facilitate research in the epidemiologic and genetic predictors of disease and permitted evaluation of the effectiveness of new risk counseling, surveillance and prevention strategies. Staff training, sharing resources and administrative support were critical components to assist the community hospital to develop a high-risk program. Formal and on-going inservice training in cancer genetics, breast cancer risk and genetic educational resources, telephone consultation, DNA blood collection procedures, and continuous monitoring were necessary for implementation and coordination of a community-based risk registry. The establishment of an Advisory Panel helped address additional issues of informed consent, reimbursement, and community-based counseling strategies. This project demonstrates that with appropriate resources and support, it is feasible to establish a registry for individuals at high risk for breast cancer and further our understanding of the genetic and epidemiologic basis of the disease
Targeting Breast Cancer With Anti HER2/neu Diabodies ( )
5 editions published between 1999 and 2003 in English and held by 5 WorldCat member libraries worldwide
The objective of this proposal is to develop new therapeutic reagents for breast cancer. It is our hypothesis that improved diabody-based molecules with affinity for HER2/neu can be engineered and will prove to be effective vehicles for the RIT of breast cancer. The first Technical Objective (T.O.) focuses on the optimization of the production of the selected diabody and the identification of the optimal radionuclide and labeling strategy for diabody-based RIT. This T.O. also involves an investigation into the impact on diabody targeting and RIT of a variety of factors likely to be encountered in a clinical setting. These include the degree of antigen density, the route (i.v. bolus or continuous infusion) and frequency of administration, the presence of disseminated disease, and the effect of antigen expression on normal tissues. Completion of these experiments will set the stage for proceeding to the clinical evaluation of diabody-based targeting of breast cancer in our second Technical Objective. The clinical component of this proposal (to be initiated in year 3) will entail a Phase I radioimmunoimaging and radioimmunoguided surgery trial designed to elicit information on the dosimetry, specificity and tumor penetration properties of radiolabeled C6.5 diabody, and will assess the RIT potential of this molecule
Fox Chase Cancer Center : Scientific Report, 1998 basic science, medical science, population science by Fox Chase Cancer Center( Book )
2 editions published between 1998 and 1999 in English and held by 5 WorldCat member libraries worldwide
Quality of Life After Prophylactic Oophorectomy ( )
5 editions published between 2001 and 2005 in English and held by 5 WorldCat member libraries worldwide
While an increasing number of women at risk for ovarian cancer are being identified through awareness efforts and risk assessment programs, a gap still exists in the known psychological and physical sequelae of preventive surgery options offered to these women. To meet the needs of women seeking information about the effects of prophylactic oophorectomy, this pilot study will provide significant information on the broader quality of life issues and physical changes following surgery. In order to make informed decisions about their choices, women considering prophylactic oophorectomy need scientific data on the hormonal and other physical consequences of surgery, and on the potential alterations in their emotional and social well being. They also need the opportunity to choose from an array of coping strategies to manage their health decisions. Studying multidimensional quality of life issues will contribute to the knowledge base about the short and long-term effects on physical, emotional, cognitive, sexual and social functioning following oophorectomy and will contribute to the development of optimum medical and alternative therapy strategies to deal with post-surgical changes. As important, it will also identify issues and needs faced by women who make the choice not to undergo surgery
Identification of Two Candidate Tumor Suppressor Genes on Chromosome 17p13.3: Assessment of Their Roles in Breast and Ovarian Carcinogenesis ( Book )
5 editions published between 1997 and 2001 in English and held by 5 WorldCat member libraries worldwide
We have identified a region of less than 30 kbp, on chromosome 17p13.3 by allelic loss mapping, which is altered in>50% of the breast tumors analyzed. Using positional cloning techniques we have identified several genes, one which we refer to as OVCA2, that fall within this critical region. To date, we have found that: (1) OVCA2 is a new gene residing in a chromosomal region which is frequently lost in breast, brain, colon, ovarian tumors, acute myeloid leukemia and myelodysplastic syndromes, (2) OVCA2 is a secretory protein which is highly evolutionarily conserved, (3) OVCA2 (25 kDa) is proteolytically processed to its mature form (21 kDa), (4) p21 is present in normal blood serum and in breast nipple aspirate fluid, (5) both forms of OVCA2 are present in a variety of tissues, including mammary epithelium, (6) secretion of OVCA2 into the breast lumen is dependent on the developmental stage of the mammary gland, and (7) secreted OVCA2 appears to be lower in most breast tumors, relative to normal mammary epithelial cells. The recent detection of p21OVCA2 in normal serum and NAF, suggests that OVCA2 could be a new hormone with an important paracrine function. Identifying the potential role of OVCA2 in the development and the pathogenesis of the breast might ultimately help us to better understand the disease and to plan more effective treatment strategies
Cognitive-Affective Predictors of the Uptake of, and Sustained Adherence to, Lymphedema Symptom Minimization Practices in Breast Cancer Survivors ( )
5 editions published between 2003 and 2007 in English and held by 5 WorldCat member libraries worldwide
Approximately 20-30% of women develop lymphedema (LE) following breast cancer treatment Effective symptom management requires that women recognize early signs of lymphedema, and maintain precautionary practices over time. Data indicates that knowledge and use of symptom minimization precautions are poor. Little is known about how breast cancer survivors perceive their LE risk, and the cognitive-affective factors that promote the uptake and adherence to LE symptom%) minimization precautions. Guided by the Cognitive-Social Health Information Processing (C-SHIP) model, we are conducting a longitudinal study, to assess barriers and facilitators associated with knowledge and adherence to LE symptom-minimization practices among breast cancer survivors. We are exploring the mediating role of cognitive-affective variables, and the moderating role of attentional style, on knowledge, uptake and adherence. Our preliminary analysis shows a correlation between high monitoring and more knowledge of lymphedema risks compared to low-monitoring styles. We are surveying levels of knowledge, and practice of symptom minimization precautions at baseline, 6-, and 12-month follow-up. Although many women are aware of LE minimization practices, data suggest that they are not incorporating the recommendations into their daily lives. Further, psychosocial factors play a role in the uptake of LE symptom-minimization practices, and sustained adherence over time
Facilitating Treatment Decision Making, Adjustment, and Coping in Men Newly Diagnosed with Prostate Cancer ( )
4 editions published between 2001 and 2004 in English and held by 4 WorldCat member libraries worldwide
The study evaluates an intervention designed to facilitate treatment decision making, adjustment, and coping among early-stage prostate cancer patients and their spouse/partners, in a randomized controlled trial. The intervention is based on the Cognitive-Social Health Information Processing (C-SHIP) framework that postulates that decision making is determined by cognitive factors (i.e., perceptions about vulnerability; expectancies and beliefs; values and goals), affective factors (i.e., concerns and worry about the disease and its treatment), as well as self-regulatory skills (i.e., the ability to manage distress and effectively execute recommended behaviors) . To date, we have 300 couples enrolled in the study; 6 month follow-up questionnaires have been sent to 232 couples with 205 patients (88%) and 160 (69%) spouses/partners completed; 12-month follow-up questionnaires have been sent to 182 patients and 160 spouse/partners who remain in the study. We now have a total of 166 patients (91% return) and 150 spouse/partners (94% return) who have completed all of the required assessment for the study. Preliminary data analyses point to the acceptability and efficacy of the Cognitive and Affective Reactions and Expectations (CARE) intervention compared to General Health Intervention (GHI), not only in the short-term but also in the long-term at 6-months post baseline
Evaluation of Feasibility for a Case-Control Study of Adrenal Androgen Production in Postmenopausal Women With Breast Cancer ( )
4 editions published between 2003 and 2006 in English and held by 4 WorldCat member libraries worldwide
Postmenopausal women with elevated serum estrogens and androgens are at an increased risk of breast cancer. Dehydroepiandosterone sulfate (DHEAS) is secreted only by the adrenals, and elevated serum DHEAS levels in postmenopausal women who develop breast cancer suggest increased adrenal androgen production. We will evaluate the feasibility of conducting a case-control study that uses adrenocorticotropic hormone (ACTH) stimulation tests to determine if postmenopausal women who develop breast cancer secrete more adrenal androgens, which are converted to estrogens in peripheral tissues, in response to ACTH stimulation compared to unaffected women. Hypotheses to be tested in the full-scale study are: 1) greater adrenal responsiveness to ACTH contributes to elevated serum concentrations of androgens and estrogens in postmenopausal women who develop breast cancer; and 2) increased adrenal androgen production in postmenopausal women with breast cancer is related to increased enzyme activity at a specific step in steroidogenesis. Specific aims of the feasibility study are: 1) determine the feasibility of a full-scale study; 2) gather preliminary data on basal and ACTH stimulated serum concentrations of dehydroepiandosterone (DHEA), androstenedione, testosterone, estradiol, and estrone in women with breast cancer compared to controls. A case-control study will be conducted at FCCC
Scientific report by Pa.) Institute for Cancer Research (Philadelphia( )
in English and held by 4 WorldCat member libraries worldwide
Ovarian Cancer Prevention Program ( )
4 editions published between 1999 and 2002 in English and held by 4 WorldCat member libraries worldwide
The goals of this research are to develop interdisciplinary studies of the etiology, biology and prevention of ovarian cancer. Project I, Ovarian Cancer Consortium has registered 293 participants including 97 ovarian cancer patients representing 165 families. The Core Laboratory has collected, processed and banked biospecimens from 235 subjects. Project II, Facilitating Decision Marking About Prophylactic Oophorectomy: baseline data on 68 women are available for preliminary analysis; 10 women, (14.7%) made a decision about having prophylactic oophorectomy while 53 women (77.9%) have not made a decision, and 5 women (7.4%) did not answer the questionnaire. Five of the 10 women who made a decision have gone on to have prophylactic oophorectomy. Project III, Phase II Chemoprevention Study of Ovarian Cancer: this placebo-controlled randomized protocol using 4HPR has been written, approved by the Dept. of Defense, the National Cancer Institute Chemoprevention Branch, and the FDA. It has been offered to the Gynecologic Oncology Group for implementation throughout the country by interested gynecologists. Data entry and quality control systems have been established and 14 different case report forms are finalized. To data, four women have signed consent forms, three were enrolled in the Ovarian Tissue Donation Portion of the study, and one has randomized to treatment and completed her prophylactic oophorectomy in March 2000
Antibody - Pretargeted Cytokine Therapy of Cancer ( )
4 editions published between 2000 and 2003 in English and held by 4 WorldCat member libraries worldwide
We hypothesize that the selective accumulation of systemically administered cytokines at tumor sites can alter tumor microenvironments to favor the induction of anti-tumor immune responses. We further hypothesize that this can be accomplished by pre-targeting tumors with antibody streptavidin immunoconjugates and then administering biotinylated cytokines. The purpose of this research program is to identify antibody-pretargeted cytokine therapy strategies that lead to tumor-selective cytokine accumulation, the development of host inflammatory cell infiltrates in tumor, and the induction of tumor- specific immunity. The ultimate goal of this research is to identify candidate strategies for clinical development, alone or in combination with tumor vaccines. In the first year of this award we have made significant progress toward achieving these goals. Interleukin-2 (IL-2) has been biotinylated, and its biological properties have been thoroughly characterized. We have obtained a streptavidin-conjugated monoclonal antibody that recognized the Ep-CAM tumor antigen that is frequently overexpressed in breast cancer specimens. Animal experiments to characterize the biodistribution properties of the antibody - streptavidin conjugate and of the conjugate admixed with biotinylated IL-2 are underway, and pretargeting experiments are about to commence
Pharmacogenetic Factors Contributing to Variation in Response to Tamoxifen and Raloxifene ( )
4 editions published between 2001 and 2004 in English and held by 4 WorldCat member libraries worldwide
The purpose of these studies is to elucidate the pharmacogenetic factors that contribute to variation in human response to tamoxifen (TAM) and raloxifene (RAL). We had previously identified and partially characterized common genetic polymorphisms in two human drug-metabolizing genes, SULT1A1 and UGT1A6. We hypothesized that these polymorphisms contributed to variation in TAM or RAL metabolism. These studies were divided into three aims with the purpose of: 1) biochemically characterizing the contribution of these enzymes to the metabolism of TAM and RAL; 2) developing cell model systems to study allele-specific differences in cellular response to these molecules and; 3) perform a clinical pharmacogenetic study to evaluate the association of common genetic polymorphisms in drug metabolizing genes with variable clinical response to TAM. Thus far we have determined that SULT1A1 and UGT1A6 contribute to the inactivation of 4-hydroxytamoxifen (OHT), the active metabolite of TAM, and that a separate enzyme, UGT1A9 catalyzed the glucuronidation of RAL. We have determined genotype/phenotype correlation for UGT1A6 alleles in a bank of human liver tissue and have generated HEK 293 cell lines that stably express each of the four UGT1A6 allozymes. The UGTlA6 *2 allozyme, when expressed homozygously, is associated with high UGT1A6 activity. We established MCF-7 breast cancer cell lines stably expressing the wild type and variant SULT1A1 alleles and have measured allele-specific differences in the response of these cells to estrogens and OHT. These studies suggest that pharmacogenetic factors might contribute to variable cellular response to antiestrogens
Scientific report by Pa.) Institute for Cancer Research (Philadelphia( Book )
1 edition published in 1986 in English and held by 4 WorldCat member libraries worldwide
The Nuclear Death Domain Protein p84N5; a Candidate Breast Cancer Susceptibility Gene ( )
4 editions published between 2004 and 2007 in English and held by 4 WorldCat member libraries worldwide
Besides family history of cancer and an individual's age, no single etiologic factor can identify women at an increased risk for the disease. Approximately 10% of all cases of breast cancer exhibit a familial pattern of incidence. Efforts to identify the genetic basis of familial breast cancer reached fruition some years ago, when the breast-cancer susceptibility genes, BRCAl and BRCA2 were identified. However, recent studies have suggested that mutations in these genes are associated with a smaller number (20 to 60%) of hereditary breast cancer families than originally estimated, especially in studies that have been based on population- based family materials. Several groups including ours are searching for additional breast cancer susceptibility genes using whole genome scanning approaches, but the success of many of these approaches depend on the underlying heterogeneity of the remaining cancer susceptibility loci. The failure to date to identify additional breast cancer susceptibility genes associated with a high risk of disease suggests that more than one may exist. We have taken the approach that the next BRCA genes will be those that encode for proteins whose functions are linked to important cell regulatory pathways. We have recently found one such candidate BRCA3 protein, referred to as p84N5
Reversal of Multidrug Resistance in Breast Cancer ( )
4 editions published between 1994 and 1997 in English and held by 4 WorldCat member libraries worldwide
Drug resistance is a major obstacle in the treatment of cancer. The multidrug resistance gene (MDR1) encodes an energy dependent drug efflux pump, P170, that confers cellular resistance to multiple therapeutic agents such as anthracyclines, vinca alkaloids, epipodophyllotoxins, taxol, and actinomycin-D. MDR1 gene expression is tumor specific in both de novo resistant tumors and those that acquire drug resistance following chemotherapy. The central role of P-170 in this multidrug resistance (MDR) phenotype suggests that modulation of either MDR1 gene expression or the function of P-170 may provide an effective means of clinically reversing drug resistance. Our data show that MDR1 gene expression is important in breast cancer resistance. The role of the MDR1 gene in breast cancer treatment will be further defined by sequentially determining MDR1 gene expression pre- and post-treatment with doxorubicin in the context of prospective clinical trials. In addition, this study will allow a correlation of MDR1 gene expression and clinical outcome. To determine what level of MDR1 gene expression is clinically significant, various molecular methods of determining MDR1 gene expression, including immunohistochemistry and quantitative reverse transcription followed by polymerase chain reaction, will be evaluated. MDR can be reversed in vitro and recent data from the in vivo transgenic mouse model suggests that combining MDR modulators such as cyclosporine and quinine, may have an advantage over either alone. We will test this hypothesis in a Phase I study of cyclosporine A and quinine as MDR reversers of vinblastine resistance. Together these studies will address the major goal of circumventing drug resistance in breast cancer
 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.65 (from 0.00 for Tailored C ... to 1.00 for Establishm ...)
Alternative Names
Languages
English (79)